Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing first- and best-in-class cellular immunotherapies for hematological cancers and solid tumors, as well as orphan inherited blood diseases.
Our product candidates are differentiated by the inclusion of powerful molecular switches designed to eliminate, reduce or activate therapeutic cells, and thereby potentially provide greater efficacy and safety compared to the current generation of cell therapies. Our approach has yielded highly encouraging results to date from our lead BPX-501 program in the haploidentical transplant setting, as children with hematological cancers and life-long genetic blood diseases were able to leave the hospital in remission or disease-free, respectively. We believe this reflects the promise of our cellular control therapies to transform standard of care—and the lives of patients and their families. We have orphan drug designation from the U.S. FDA and the EMA for both BPX-501 for treatment in HSCT, and for activator agent rimiducid for the treatment of GvHD.
We have ongoing Phase 1 clinical trials with our BPX-601 GoCAR-T product candidate in the initial indication of non-resectable pancreatic cancer, and with our BPX-701 TCR product candidate in refractory or relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
To date, CAR T and TCR therapies have only been shown to be broadly effective in certain blood cancers, and if they are to become a viable option in solid tumors, new approaches will be needed. We believe our proprietary cellular control CAR T and TCR immunotherapies may bring greater levels of efficacy and safety to the treatment of solid as well as hematologic tumors—addressing enormous unmet needs and a much broader market opportunity.